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Abstract: Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and
mortality following allogeneic stem cell transplantation. Current therapies, including corticosteroids
and calcineurin inhibitors, are only effective in roughly 50% of cases; therefore, new treatment
strategies are under investigation. What was previously felt to be a T cell disease has more recently
been shown to involve activation of both T and B cells, as well as a number of cytokines. With a
better understanding of its pathophysiology have come more expansive preclinical and clinical trials,
many focused on B cell signaling. This report briefly reviews our current understanding of cGVHD
pathophysiology and reviews clinical and preclinical trials with B cell-targeted agents.
Keywords: chronic graft-versus-host disease; B cell; rituximab; ibrutinib
1. Introduction
Chronic graft-versus-host disease (cGVHD) continues to be a major cause of morbidity and
mortality following allogeneic hematopoietic stem cell transplantation (SCT) [1]. The cumulative
incidence ranges from 20–77% [2], but is rising as factors that increase the rate of cGVHD—such as
older recipient age, use of donor peripheral blood, and non-HLA identical donors—become more
common, and transplant-related mortality decreases [3,4]. Assessing the response to therapy and
interpreting clinical trials is made difficult by the lack of standardized definitions and response criteria
for cGVHD [5], however, it has been widely reported that cGVHD adversely impacts treatment-related
mortality and overall survival following allogeneic SCT [6,7].
The pathophysiology of cGVHD is complex [3,8] and incompletely understood and as a
result, effective therapies and controlled trials are lacking [9]. Long thought to be a T cell disease,
emerging evidence supports a role for B cells in the development of cGVHD [10,11], which carries
important implications for prevention and treatment. Below we will briefly review the pathophysiology
of cGVHD with a focus on B cell mechanisms, then we will outline both preclinical and clinical trial
data on B cell-targeted therapies for the prevention and treatment of cGVHD.
2. Pathogenesis of Chronic Graft-Versus-Host Disease (cGVHD)
The presentation of cGVHD shares similarities with other autoimmune disorders, including
lichen planus, scleroderma, bronchiolitis obliterans (BO), primary biliary cirrhosis, immune cytopenias,
and chronic immunodeficiency [1,10]. It commonly presents within one year of allogeneic SCT, with a
median time of 4–4.5 months following transplantation [12]. The most common manifestations are
in the skin, mouth, liver, eyes, lung, GI tract, joints, and hematopoietic system [3]. Historically,
cGVHD was classified as limited versus extensive, however, given its limitations, a number of
classification and grading systems were introduced, including the Johns Hopkins model, the CIBMTR
grading system, and the NIH consensus criteria for GVHD sensitivity. The NIH criteria, which include
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“diagnostic features” requiring no further workup to diagnose cGVHD and “distinctive features”
requiring tissue confirmation for diagnosis, are widely used to diagnose cGVHD [13].
Given its overlap with a number of distinct autoimmune disorders, it follows that cGVHD is
a complex, heterogeneous disease. While a major predictor of cGVHD is the development of prior
acute GVHD (aGVHD), the pathogenesis of cGVHD involves more than simply prolongation of
aGVHD [2]. aGVHD is primarily a T cell disease, occurring as a result of donor T cell activation in
response to major or minor histocompatibility mismatch or gene polymorphisms. Donor-derived T
cells are activated primarily through Th1 cytokines (IL-2, IFN-γ, and TNF-α) and then migrate
from lymphoid tissue to target organs, where they cause damage to epithelial cells via apoptosis
and cytokine release [14]. There is a direct relationship between the acute and chronic forms of
GVHD. Approximately two-thirds of patients undergoing allogeneic SCT who develop cGVHD
had earlier aGVHD [15,16], which suggests a prominent role for T cells in cGVHD pathogenesis.
Proposed mechanisms include: late manifestations of alloreactive donor T cells; thymic damage during
aGVHD causing T cell dysregulation and failure to delete autoreactive T cells [8]; a downstream effect
of immunosuppressive treatment of aGVHD; or an associated but independent epiphenomenon [16].
Th17 cells and their primary cytokine, IL-17, have been implicated in sclerodermatous cGVHD [17] and
high levels of IL-17 have been found in skin cGVHD [10]. Unlike in aGVHD, however, Th2 cytokines
seem to predominate in cGVHD [10]. Furthermore, one third of patients develop cGVHD without any
prior history of aGVHD. More recent research suggests cGVHD involves a complex interplay between
T and B cells.
B Cell Role in cGVHD Pathogenesis
Animal and human studies have in recent years demonstrated a prominent role for B cells
in cGVHD development. An early suggestion of this came from the one study demonstrating
autoantibodies in patients with cGVHD [18]. In another study of 121 male patients receiving an
allogeneic SCT from female donors, antibodies directed against minor histocompatibility antigens
encoded by genes on the Y chromosome were found in 52% of recipients, and these correlated with
cGVHD [19]. A relationship between T and B cells was demonstrated in murine cGVHD models by
Zhang et al., who showed that development of cGVHD in mice required both donor CD4+ CD25− T
cells and B cells [20]. Preclinical studies have shown that germinal centers (GC), where T follicular
helper (TFH) cells interact with B cells, are increased in size and number in mice with cGVHD, and that
development of cGVHD requires GC formation [21–23]. However, it remains unclear if murine models
of cGVHD can accurately represent the pathophysiology of cGVHD in humans receiving allogeneic SCT.
B cell homeostasis has also been implicated in cGVHD development. B cell activating factor (BAFF)
plays an important role in B cell tolerance by limiting B cell receptor (BCR)-mediated apoptosis [24].
A study of BCR transgenic mice showed that BAFF overexpression selectively promoted survival
of autoreactive B cells by rescuing them from peripheral deletion [25]. High levels of BAFF after
allogeneic SCT, coupled with depletion of B cells by the conditioning regimen, prevent apoptosis of
polyreactive B cells and may play a role in the development of cGVHD [24]. Additionally, lymphopenia
leads to higher BAFF concentrations because naïve B cells are unavailable to bind soluble BAFF [24],
while restoration of the naïve B cell component seems to be protective of cGVHD [26]. A study of
cGVHD patients by Sarantopoulis et al. further supports the role of altered B cell homeostasis in
cGVHD development [26]. The authors studied 20 patients with cGVHD who were previously treated
with the anti-CD20 monoclonal antibody rituximab, 11 of whom had stable or improved cGVHD
following treatment and nine of whom had progressive cGVHD. They found that all patients developed
the expected profound B lymphopenia after rituximab therapy, but that the group with progressive
cGVHD continued to have B cell depletion after a median of 25 months, while the responders recovered
their peripheral B cell pools, which comprised primarily naïve IgD+ B cells. Similarly, BAFF levels
increased in all patients following rituximab, but decreased in the responsive patients while remaining
persistently elevated in the unresponsive group. Responders to rituximab had significant decreases in
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CD27+ B cells—which are antigen-experienced memory B cells—whereas the B cells of unresponsive
patients demonstrated an activated phenotype [26]. Taken together, these findings suggest that
skewing of the BAFF/B cell ratio and survival of activated autoreactive B cells promote cGVHD
development. These results were confirmed in a larger prospective study of post-SCT rituximab
prophylaxis, in which patients who went on to develop cGVHD had significantly lower B cell numbers
and a higher BAFF/B cell ratio compared to those who did not develop cGVHD [27]. These studies,
along with data suggesting that higher BAFF levels predict subsequent development of cGVHD [28],
make BAFF a potentially useful biomarker for development of cGVHD, as well as a possible target for
treating it.
Enhanced B cell activation and signaling has also been implicated in cGVHD. CD27+ B cells
in cGVHD have been shown to constitutively produce IgG, which is distinct from healthy controls,
in whom antigen or BCR stimulation is required to secrete antibody [24]. Allen et al. found that
pre-GC CD27+ B cells in patients with active cGVHD were significantly larger than CD27− cells,
suggesting activation [29]. A later study also showed that B cells in cGVHD are hyper-responsive in
response to antigen stimulation, and that the BCR signaling components spleen tyrosine kinase (Syk)
and B cell linker protein (BLNK) were elevated at baseline. Further, they found that after initiation
of BCR signaling, phosphorylation by Syk and BLNK were elevated compared to patients without
cGVHD [30].
Regulatory B cells (Bregs), a subset of B cells capable of attenuating the immune response under
inflammatory conditions, may possibly play a role in cGVHD development [31]. Bregs exert their
inhibitory effect via multiple mechanisms, including secretion of the regulatory cytokines IL-10 and
TGF-β and direct cell-to-cell interaction with pathogenic T cells [31]. IL-10 producing B cells have
been shown to be deficient in human cGVHD patients [32]. Sarvaria et al. studied Bregs in cord blood,
as well as in patients with and without cGVHD [33]. They found that Bregs were enriched in cord
blood and were upregulated following allogeneic cord blood transplantation, but that Bregs were
deficient in patients who developed cGVHD.
3. B Cell Targeting in the Treatment and Prevention of cGVHD
For decades, the mainstays of therapy for cGVHD have been meticulous organ-specific care and
corticosteroids, often for at least one year in moderate-severe cGVHD (1). Prolonged corticosteroid
therapy exposes patients to significant side effects, therefore, the calcineurin inhibitors cyclosporine
and tacrolimus are often added. Still, 50–60% of patients have recurrent cGVHD symptoms
within two years and require second-line therapy [5]. Many immunosuppressive agents have
been studied in combination with corticosteroids—including mycophenolate mofetil, azathioprine,
thalidomide, and hydroxychloroquine—with no benefit [1]. No current standard exists for second-line,
steroid-refractory cGVHD [11].
3.1. B Cell Depletion in the Treatment and Prevention of cGVHD
3.1.1. Rituximab
In an effort to improve upon these primarily T cell-directed therapies, other approaches have
targeted B cells. The efficacy of B cell targeted agents in cGVHD was discovered somewhat incidentally.
Ratanatharathorn et al. used rituximab in a patient with refractory thrombocytopenia and oral
and ocular manifestations of cGVHD following allogeneic SCT, and found that, in addition to an
improvement in her platelet count, her cGVHD symptoms also abated and immunosuppression was
successfully stopped [34]. Since then, multiple small case series have demonstrated mixed results in
steroid-refractory cGVHD [35–42].
In order to better understand the role of rituximab in treating cGVHD, multiple prospective
studies have evaluated rituximab in refractory cGVHD, the largest of which by Cutler et al. included
20 patients treated with rituximab (375 mg/m2) for between one and three cycles, with a 70% response
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rate and two CRs at one year of follow-up. The median dose of prednisone was reduced from
40 mg/day to 10 mg/day, and the authors showed a sustained decrease in antibody titers to minor
histocompatibility antigens encoded on the Y chromosome [43]. A small prospective study with seven
patients demonstrated a slightly lower overall response rate (ORR) of 43% [44]. Another prospective
study of 20 patients with cGVHD who received one four-week course of rituximab showed an ORR of
62%, with increased B cell number in responders [45]. More recently, a prospective phase II trial using
either imatinib or rituximab for sclerodermatous cGVHD demonstrated a response in 19/72 (26%)
of patients. High levels of CD27+ activated B cells before treatment predicted response in patients
receiving rituximab, but not those receiving imatinib [46].
Rituximab has also been studied in the first-line setting in combination with corticosteroids.
A study of 35 treatment-naïve patients with cGVHD showed a clinically meaningful response
rate—defined as a PR or CR with prednisone <0.25 mg/kg/day—of 43%, which was sustained
through one year [47]. Predictors of response included high levels of pre-treatment naïve CD19+
CD27− B cells and low BAFF levels. IgG and IgM antibodies and specific B cells to male-specific
H-Y antigens were measured in the 15 male recipients from female donors, and among patients who
were positive for H-Y IgG and IgM before rituximab, all responders had undetectable levels following
treatment. Meanwhile, three of four non-responders remained positive for H-Y IgG. A similar trend
was observed in H-Y antigen specific B cells [47].
Last, rituximab has been evaluated as a preventive strategy for the development of cGVHD.
The largest phase II trial carried out to date included 65 patients who received rituximab infusions at
three, six, nine, and 12 months post-allogeneic SCT [27]. At two years post-transplantation, the rates
of cGVHD and steroid-requiring cGVHD were 48% and 31%, respectively, both of which were lower
than a control cohort. The rates decreased further to 35% and 23%, respectively, in patients with a
sibling donor. Further, this study included only patients receiving peripheral blood SCT, who have a
greater risk of cGVHD development. Treatment-related mortality (5% vs. 19%) and overall survival
(71% vs. 56%) at four years were both significantly better in the rituximab-receiving group than the
control cohort. The authors also noted that the BAFF/B cell ratio was significantly higher in patients
who developed cGVHD (27), suggesting that rituximab exerts its protective effect partly through
preserving B cell homeostasis. Another prospective study of rituximab given weekly from days +56–77
post-transplantation reported a cGVHD incidence of 20% [48], though these patients all received
conditioning with antithymocyte globulin (ATG), which is associated with lower rates of cGVHD [49].
In this study, rituximab was associated with total prevention of H-Y antibodies in the 10 male recipients
from female donors [49]. Not all studies of rituximab prophylaxis have demonstrated an effect on
cGVHD development. A phase II trial in 84 patients demonstrated no effect of rituximab on cGVHD
development at one year (46%, vs. 42% in the group not receiving rituximab). This study was marked
by very high rates of aGVHD requiring an amendment of the protocol that mandated the use of ATG,
making interpretation of the results more difficult [50]. Finally, a large retrospective CIBMTR study
comparing rituximab-containing conditioning regimens to regimens without rituximab in B-NHL
patients showed no effect on cGVHD [51]. The mixed evidence with rituximab may be in part because
of the deleterious effect on B cell homeostasis by inducing profound B lymphopenia.
3.1.2. Ofatumumab and Bortezomib
A phase I trial of the humanized anti-CD20 monoclonal antibody ofatumumab in 12 cGVHD
patients with a new prednisone requirement showed a promising ORR of 67% (one CR, seven PR,
one stable disease). A sustained decrease in prednisone dose was also observed at three and six months
of follow-up [52]. A phase II study is ongoing.
The proteasome inhibitor bortezomib has been evaluated as a strategy to prevent and treat cGVHD.
It functions as an immunomodulator which can reduce alloreactive T cells and antigen-presenting
cells [53], but also depletes plasma cells and can inhibit the B cell response [54]. Koreth et al. first
demonstrated that bortezomib may help reduce cGVHD associated with HLA-mismatched unrelated
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donor SCT [53]. In this phase I/II trial, a bortezomib dose of 1.3 mg/m2 was first selected based on
maximum tolerated dose, and then given on Days +1, +4, and +7. In comparison to a contemporaneous
cohort of patients receiving grafts from matched unrelated donors, the study patients had similar
rates of cGVHD, non-relapse mortality, progression-free survival, and overall survival at one year [46].
The same authors then undertook a prospective phase II trial of 1st line bortezomib in the treatment of
cGVHD. The study included 20 evaluable patients who received three cycles of bortezomib (on days
1, 8, 15, and 22 of five-week cycles), among whom the ORR at 15 weeks was 80% (two CR, 14 PR).
Prednisone dosing was significantly reduced by week 15 [55].
Pai et al. have studied bortezomib in preclinical murine models, and are undertaking a single
arm phase I trial in patients with refractory or severe cGVHD [54]. In an early analysis of 10 patients,
6/10 received at least 60% of planned bortezomib doses, and of those patients all but one achieved at
least a partial remission. The corticosteroid dose was also reduced successfully [54].
3.2. B Cell Signaling Inhibition in the Treatment and Prophylaxis of cGVHD
3.2.1. Imatinib
The Bcr-Abl tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib—used primarily in
the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL)—inhibit BCR signaling and B cell proliferation via inhibition
of multiple tyrosine kinases, and may also dampen B cell immune responses via inhibition of Bruton’s
tyrosine kinase (BTK), a key enzyme in B cell signaling, proliferation, and cell survival [56,57].
These properties have generated interest in this class of drugs for the prevention and treatment
of cGVHD. A phase I/II trial of imatinib in 19 patients with treatment-refractory cGVHD with fibrotic
features showed an ORR of 79%, though eight patients had to discontinue the drug and impact on
steroid use was not measured [58]. A larger phase II study with 39 patients showed a response rate of
46%, defined as PR or minor responses (MR) with steroid sparing [59]. Response to therapy correlated
with three-year overall survival. A phase II crossover trial of either rituximab or imatinib showed
similar efficacy between the two agents in cutaneous sclerodermatous cGVHD, with a clinical response
rate to imatinib of 26% [46]. Dasatinib has also been reported in case series to be effective in patients
with cGVHD refractory to imatinib [60].
3.2.2. Ibrutinib
The BTK inhibitor ibrutinib, which has been approved in CLL, mantle cell lymphoma,
and Waldenstrom’s macroglobulinemia, has been studied in cGVHD for its potent B cell signaling
inhibition properties. In a preclinical murine allogeneic SCT model, ibrutinib was shown to limit
development of sclerodermatous cGVHD and to improve existing skin lesions. It had a similar
protective and therapeutic effect on pulmonary BO (61). In vivo studies showed that ibrutinib blocked
both T and B cell activation and that it limited the GC reaction and immunoglobulin deposition in the
lungs. Ibrutinib also acts as an IL-2 inducible T cell kinase (ITK) inhibitor, and this study confirmed
that both BTK and ITK are required for the development of cGVHD [61].
In response to preclinical findings, ibrutinib was studied in a phase II trial [62]. Miklos et al. found
that in 42 patients with steroid-refractory cGVHD (median prior regimens = 2), ibrutinib demonstrated
an ORR of 67%, with a durable response at ≥20 weeks and ≥32 weeks of 71% and 48%, respectively.
Five of the 28 responders successfully discontinued corticosteroids entirely. Both patient-reported
symptom score and markers of inflammation improved in patients treated with ibrutinib [62]. Based on
the results of this trial, ibrutinib received FDA approval in August 2017 for second-line treatment
of cGVHD.
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3.3. Future Directions
3.3.1. Syk Inhibition
Syk is a downstream BCR signaling enzyme that promotes B cell proliferation and survival. Syk is
overexpressed at baseline in cGVHD patients, and demonstrates greater phosphorylation following
BCR signaling compared to patients without cGVHD [30]. Fostamitinib, a potent small molecule
inhibitor of Syk, is being studied in a preclinical murine model with pulmonary cGVHD and has been
found to restore normal lung function in these mice [23]. Further, it decreased the number of splenic
GC B cells and GC reactions, which are crucial for cGVHD development [21]. In another preclinical
study, fostamitinib did not have an effect on murine sclerodermatous cGVHD, but did induce death by
apoptosis in human cGVHD cells [63]. Clinical trials using fostamitinib (NCT02611063) and the Syk
inhibitor entospletinib (NCT02701634) are ongoing in the treatment of cGVHD.
3.3.2. IL-21/IL-21R Inhibition
IL-21 is a cytokine involved in cell proliferation with receptors on T, B, and natural killer cells.
Monoclonal antibodies against IL-21 and its receptor—as well as inducible T cell costimulatory (ICOS)
and CD40, which are necessary for GC formation—have demonstrated a reduction in GC formation
and BO development in mice [22].
3.3.3. Rho-Associated Kinase 2 (ROCK2) Inhibition
Rho-associated kinase 2 (ROCK2) is a member of the ROCK family of serine-threonine kinases.
In addition to regulating cell movement, ROCK2 was recently found to regulate IL-21 and IL-17
secretion, making it an enticing target in cGVHD. A selective ROCK2 inhibitor, KD025, has been
studied in murine models of full multisystem cGVHD with BO (major histocompatibility mismatch)
and more limited sclerodermatous cGVHD (minor histocompatibility mismatch). Mice treated with
KD025 had a normalization of lung function and reduced antibody deposition in the lungs. Further,
spleens of treated mice showed reduced TFH cells and an increase in Treg cells, as well as a reduction
of STAT3 phosphorylation [64].
3.3.4. BCL6 Inhibition
BCL6 is a transcription factor that promotes GC development and TFH cell differentiation.
Murine studies suggest an increase in BCL6+ splenic T cells in cGVHD, and the small molecule BCL6
inhibitor 79-6 may reverse BO and decrease GC B cells [23].
3.3.5. EZH2 Inhibition
EZH2 is a lysine methyltransferase that works in concert with BCL6 to promote GC development.
It methylates histone and leads to gene repression, and is upregulated during the GC reaction,
allowing proliferation and affinity maturation in activated B cells [65]. Sarantopoulos et al. demonstrated
that deleting EZH2 from early B cells or splenic T cells prevents cGVHD in mice, and then showed
that the selective EZH2 inhibitor JQ-E can reverse lung cGVHD and fibrosis [23].
4. Conclusions
cGVHD is a complex process involving an interplay between T and B cells, as well as other
cytokines and immune cells. Current, first-line therapy with corticosteroids with or without calcineurin
inhibitors is often ineffective, therefore, ongoing investigation in preclinical and clinical trials is
required to better understand the disease and improve its treatment. More recent discoveries have
highlighted a prominent role for B cells in the development of cGVHD, prompting the study of B
cell-targeted therapies for the prevention and treatment of cGVHD. Rituximab has shown mixed
efficacy in steroid-refractory cGVHD and may help prevent its development. Understanding of B cell
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signaling has led to the study and recent FDA approval of the BTK inhibitor ibrutinib in refractory
cGVHD. Looking ahead, more preclinical studies will be needed to identify novel agents aimed at
B cell proliferation and GC development, and promising drugs such as the Syk inhibitors fostamitinib
and entospletinib require ongoing study in clinical trials as first- and second-line therapies.
Conflicts of Interest: The authors declare no conflict of interest.
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